Key Takeaways
- Many endocrine rare diseases begin in primary care long before specialty diagnosis.
- Commercial opportunity depends on recognition, referral and treatment initiation—not prevalence alone.
- Access, specialty pharmacy and patient support must be designed into the commercial model early.
- Organization design should reflect specialist concentration and diagnostic complexity.
Endocrinology rare disease markets demand precise understanding of how patients are recognized, referred and managed—and where treatment access breaks down.
Clinical innovation matters. Commercial discipline determines whether appropriately diagnosed patients can start and stay on therapy. PharmaKonsult’s perspective is developed further in endocrinology rare disease commercialization.
Executive opinion paper
Full article
Full article available by request only.
Contact PharmaKonsult to request the complete opinion paper.
About Joseph McCoy
Joseph McCoy is Founder and Principal Consultant of PharmaKonsult and an executive commercial strategy advisor with more than three decades of pharmaceutical and biotechnology commercial leadership experience across neuroscience, rare disease, endocrinology, institutional healthcare and specialty pharmaceuticals.
